Investigational antibiotic cefepime/zidebactam as a therapeutic option for the treatment of an unyielding empyema in a paediatric patient caused by extensively drug-resistant Pseudomonas aeruginosa: a case report.

IF 3.7 3区医学 Q2 INFECTIOUS DISEASES

European Journal of Clinical Microbiology & Infectious Diseases Pub Date : 2025-03-18 DOI:10.1007/s10096-025-05106-8

Vishnu Rao Polati, Santosh Gattu, Venkata Nagarjuna Maturu, P Swati Prakasham, Maryam Maqsood

{"title":"Investigational antibiotic cefepime/zidebactam as a therapeutic option for the treatment of an unyielding empyema in a paediatric patient caused by extensively drug-resistant Pseudomonas aeruginosa: a case report.","authors":"Vishnu Rao Polati, Santosh Gattu, Venkata Nagarjuna Maturu, P Swati Prakasham, Maryam Maqsood","doi":"10.1007/s10096-025-05106-8","DOIUrl":null,"url":null,"abstract":"Objective: Treatment option for the infections caused by MBL-producing P. aeruginosa is severely limited. Cefepime/zidebactam (WCK 5222) is a novel β-lactam/ β-lactam-enhancer combination, currently in global Phase 3 clinical development. It is reported to show a broad-spectrum in vitro activity and translational efficacy in non-clinical PK/PD models against carbapenem-resistant Gram-negative bacteria including MBL-producing P. aeruginosa. We present a case of a 13-year-old girl, suffering from tuberculosis with a refractory lung empyema caused by NDM-producing, XDR P. aeruginosa who did not respond to several rounds of colistin or aztreonam plus ceftazidime/avibactam therapies albeit effective source control, over 4 months period.Methods: The infecting organism was found to be susceptible to cefepime/zidebactam. After obtaining informed consent and necessary approvals, the patient was treated under compassionate ground.Results: The patient was treated with adult dose regimen of cefepime/zidebactam (due to higher body weight) for 21 days that led to clinical and microbiological cure.Conclusion: This case highlights both severity of the antimicrobial resistance and hope offered by an under-trial novel antibiotic.","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Microbiology & Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10096-025-05106-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Treatment option for the infections caused by MBL-producing P. aeruginosa is severely limited. Cefepime/zidebactam (WCK 5222) is a novel β-lactam/ β-lactam-enhancer combination, currently in global Phase 3 clinical development. It is reported to show a broad-spectrum in vitro activity and translational efficacy in non-clinical PK/PD models against carbapenem-resistant Gram-negative bacteria including MBL-producing P. aeruginosa. We present a case of a 13-year-old girl, suffering from tuberculosis with a refractory lung empyema caused by NDM-producing, XDR P. aeruginosa who did not respond to several rounds of colistin or aztreonam plus ceftazidime/avibactam therapies albeit effective source control, over 4 months period.

Methods: The infecting organism was found to be susceptible to cefepime/zidebactam. After obtaining informed consent and necessary approvals, the patient was treated under compassionate ground.

Results: The patient was treated with adult dose regimen of cefepime/zidebactam (due to higher body weight) for 21 days that led to clinical and microbiological cure.

Conclusion: This case highlights both severity of the antimicrobial resistance and hope offered by an under-trial novel antibiotic.

查看原文本刊更多论文

研究性抗生素头孢吡肟/齐地巴坦作为治疗广泛耐药铜绿假单胞菌引起的儿科患者顽固性脓胸的治疗选择：一个病例报告。

目的：产生mbl的铜绿假单胞菌引起的感染的治疗选择严重有限。Cefepime/zidebactam （WCK 5222）是一种新型β-内酰胺/ β-内酰胺增强剂组合，目前处于全球3期临床开发阶段。据报道，该药物在非临床PK/PD模型中对耐碳青霉烯类革兰氏阴性菌（包括产生mbl的铜绿假单胞菌）具有广谱的体外活性和转化功效。我们报告了一个13岁的女孩，患有由ndm产生引起的难治性肺脓肿，XDR铜绿假单胞菌谁没有响应多轮粘菌素或阿唑南加头孢他啶/阿维巴坦治疗，尽管有效的来源控制，超过4个月的时间。方法：发现感染菌对头孢吡肟/齐德巴坦敏感。在获得知情同意和必要的批准后，病人在同情的基础上得到治疗。结果：患者接受头孢吡肟/齐德巴坦成人给药方案治疗21 d（因体重增高），临床及微生物治愈。结论：该病例突出了抗菌素耐药性的严重程度和正在试验的新型抗生素所带来的希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Clinical Microbiology & Infectious Diseases 医学-传染病学

CiteScore

10.40

自引率

2.20%

发文量

138

审稿时长

1 months

期刊介绍： EJCMID is an interdisciplinary journal devoted to the publication of communications on infectious diseases of bacterial, viral and parasitic origin.